



PATIENT ADVISORY BOARD

2027 Sponsorship Prospectus

About the Cholangiocarcinoma Foundation

The Cholangiocarcinoma Foundation's (CCF) mission is to find a cure and improve the quality of life for those affected by cholangiocarcinoma (CCA). Founded in 2006 in Salt Lake City, Utah, by a family who lost a loved one to the disease, CCF has grown into a global leader in patient support, education, advocacy, and funding basic, clinical, and translational research. CCF's core values are patients first, collaboration, innovation, and urgency.

About our Patient Advisory Boards

A Patient Advisory Board (PAB) offers companies the opportunity to gain direct, non-binding insights from individuals personally affected by CCA. Designed to enhance understanding of the patient journey and inform trial design, communication strategies, and patient support programs, the PAB connects industry companies with carefully selected patients and caregivers, chosen based on the company's specific needs and objectives. PABs can be conducted **virtually or in person**, depending on the company's preferences and goals.

Companies may utilize a PAB to:

- **Refine clinical trial protocols** through patient and caregiver feedback on eligibility, visit burden, and informed consent.
- **Understand the patient journey** to identify barriers to diagnosis, treatment, and clinical trial participation.
- **Evaluate educational materials** to ensure they are clear, patient-friendly, and effective.
- **Explore unmet needs and support gaps** across different treatment stages to help inform future services, educational resources, and patient support programs.
- **Gather insights on emerging topics** such as biomarker testing, adverse event management, and digital health tools to better understand the patient perspective and evolving needs.

Meeting Format

Duration: 2 hours via Zoom or in-person

Participants: 6-10 patients and/or caregivers recruited by CCF, selected based on company needs

Moderator: The sessions are confidential and collaborative and typically moderated by Melinda Bachini, CCF's Chief Patient Officer. An alternative moderator may be selected based on the topic, geographic region, or company preference to ensure the most relevant expertise and facilitation.

Discussion Style: Combination of company presentation, open dialogue, prepared questions, real-time polling, and feedback.

Timeline: Planning and execution typically take 6-8 weeks from the time CCF receives the pledge.



For more information, contact:

Kaylin Allenbrand, Director of Corporate Partnerships, kaylin.allenbrand@curecca.org

2027 Patient Advisory Board Benefits

By participating in a Patient Advisory Board, your company will receive:

- **Direct Patient Insights**
Engage with 6–10 carefully selected patients and/or caregivers whose experiences align with your study or initiative, providing real-world perspectives that help inform program development, trial design, and patient-centered decision-making.
- **Customized Participant Selection**
Leverage CCF's extensive patient and caregiver network to ensure diverse representation across disease stage, treatment history, geography, demographics, and other characteristics aligned with your meeting objectives.
- **Facilitation by Leading Experts**
Meetings are moderated by Melinda Bachini, CCF's Chief Patient Officer and 16-year cholangiocarcinoma survivor, ensuring thoughtful discussion, meaningful engagement, and a trusted patient perspective throughout the session.
- **Full-Service Management**
CCF provides comprehensive management of Patient Advisory Boards, supporting industry partners from planning through post-meeting follow-up. Services include:
 - **Meeting planning and facilitation:** CCF will organize, host, and facilitate the Patient Advisory Board in collaboration with the sponsoring company. Meeting formats may include company presentations, prepared questions, polling, open discussion, or other mutually agreed-upon elements.
 - **Participant recruitment and coordination:** CCF will recruit patient and caregiver participants aligned with the sponsoring company's objectives and desired participant criteria, coordinate scheduling, and manage participant communications.
 - **Agenda and materials preparation:** CCF will develop and distribute meeting agendas, briefing materials, prepared questions, and any relevant pre-meeting materials to ensure participants are prepared for the discussion.
 - **Logistics and event execution:** CCF will manage meeting logistics, including virtual hosting and technical support or on-site coordination for in-person meetings. For in-person programs, this may include coordination of meeting space, A/V needs, refreshments or meals, and other event logistics.
 - **Participant agreements, honoraria, and reimbursements:** CCF will coordinate participant confidentiality agreements, manage honoraria, and process approved travel, parking, or related reimbursements, if applicable.
 - **Post-meeting follow-up and reporting:** CCF will conduct a post-event survey and provide a summary report outlining key findings, themes, and participant feedback.
- **Flexibility in Format**
Choose between virtual or in-person delivery based on your team's objectives, timeline, and budget. Pricing varies depending on the selected format.
- **Visibility and Relationship-Building**
Demonstrate your commitment to patient-centered research while strengthening relationships with the cholangiocarcinoma community through collaboration with one of the field's most respected patient advocacy organizations.

Investment

Virtual Patient Advisory Board: **\$40,000**

In-Person Patient Advisory Board: **\$60,000**

(in conjunction with a CCF-hosted event, such as a Regional Symposium or Annual Conference).

Patient Advisory Boards conducted outside of a CCF-hosted event may incur additional fees.

CCF's obligation is fulfilled by delivering on the commitments articulated in this prospectus for the year or years indicated above, as well as by the value the sponsor receives from its association with CCF's intellectual capital, partners, and constituents.